» Articles » PMID: 24692575

Disease Activity and Prognostic Factors in Juvenile Dermatomyositis: a Long-term Follow-up Study Applying the Paediatric Rheumatology International Trials Organization Criteria for Inactive Disease and the Myositis Disease Activity Assessment Tool

Overview
Specialty Rheumatology
Date 2014 Apr 3
PMID 24692575
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The aims of this study were to examine disease activity by the Paediatric Rheumatology International Trials Organization (PRINTO) criteria for inactive disease and the Myositis Disease Activity Assessment Tool (MDAAT) in JDM patients after long-term follow-up and to identify predictors of these outcomes.

Methods: A retrospective inception cohort of 59 patients diagnosed with JDM was clinically examined in a cross-sectional study a median of 16.8 years (range 2.0-38.1) after symptom onset. Patients were divided by the PRINTO criteria into clinically inactive and active disease. Disease activity was also measured by MDAAT and other validated tools. Medical records were reviewed for early disease variables and medication.

Results: By the PRINTO criteria, 31/59 (51%) patients were active and 29/59 (49%) were inactive. By MDAAT, 43/59 (73%) of the patients had measurable disease activity, most commonly found in the skin (59%) and skeletal (27%) systems. MDAAT showed moderate to strong correlations with other disease activity measures (rsp 0.39-0.87, P < 0.05) except for muscle enzymes. Active patients had higher disease activity than inactive patients measured by MDAAT (P < 0.001) and other disease characteristics (all P ≤ 0.002) except for patients' global assessment of disease activity. After controlling for gender and follow-up time, calcinosis during disease-course predicted high MDAAT, age<9 years at diagnosis predicted active disease and organ damage present 6-12 months post diagnosis predicted both outcomes.

Conclusion: After 16.8 years, 51-73% of JDM patients had active disease. Disease activity by the PRINTO criteria and MDAAT were moderately to highly associated with most other disease characteristics and was predicted by early damage.

Citing Articles

Disease activity in patients with idiopathic inflammatory myopathy according to time since diagnosis and positivity to antisynthetase autoantibodies: data from the Myo-Spain registry.

Cobo-Ibanez T, Castellvi I, Pros A, Dominguez-Alvaro M, Nuno-Nuno L, Martinez-Barrio J Arthritis Res Ther. 2025; 27(1):5.

PMID: 39780297 PMC: 11707992. DOI: 10.1186/s13075-024-03471-x.


Control of dermatomyositis skin disease activity lags behind control of muscles disease activity during the early treatment stages of classic dermatomyositis: A retrospective, single-centre study.

Bhatt H, Flatley E, Cooper K, Jorgensen T, McDonald C, Fernandez A Skin Health Dis. 2024; 4(3):e357.

PMID: 38846685 PMC: 11150736. DOI: 10.1002/ski2.357.


Biologic drugs in the treatment of juvenile dermatomyositis: a literature review.

Sener S, Cam V, Ozen S, Batu E Clin Rheumatol. 2023; 43(2):591-602.

PMID: 37582998 DOI: 10.1007/s10067-023-06740-3.


Transition readiness in adolescents with juvenile idiopathic arthritis and their parents: Our single-center experience.

Lazarevic D, dordevic S, Novakovic D, Zecevic M, Susic G Arch Rheumatol. 2023; 37(3):411-416.

PMID: 36589608 PMC: 9791543. DOI: 10.46497/ArchRheumatol.2022.9219.


Juvenile Dermatomyositis: what comes next? Long-term outcomes in childhood myositis from a patient perspective.

Boros C, McCann L, Simou S, Cancemi D, Ambrose N, Pilkington C Pediatr Rheumatol Online J. 2022; 20(1):102.

PMID: 36384526 PMC: 9670456. DOI: 10.1186/s12969-022-00754-y.